These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

438 related items for PubMed ID: 35811317

  • 1. Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer.
    Jia K, Chen Y, Sun Y, Hu Y, Jiao L, Ma J, Yuan J, Qi C, Li Y, Gong J, Gao J, Zhang X, Li J, Zhang C, Shen L.
    BMC Med; 2022 Jul 11; 20(1):223. PubMed ID: 35811317
    [Abstract] [Full Text] [Related]

  • 2. Unlocking the potential of HHLA2: identifying functional immune infiltrating cells in the tumor microenvironment and predicting clinical outcomes in laryngeal squamous cell carcinoma.
    Li W, You J, Xue H, Liu Y, Chen J, Zheng X, Chen L, Wu C.
    Cancer Immunol Immunother; 2024 Aug 06; 73(10):207. PubMed ID: 39105870
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Analysis of Immunological Characteristics and Genomic Alterations in HPV-Positive Oropharyngeal Squamous Cell Carcinoma Based on PD-L1 Expression.
    Xu SM, Shi CJ, Xia RH, Wang LZ, Tian Z, Ye WM, Liu L, Liu SL, Zhang CY, Hu YH, Zhou R, Han Y, Wang Y, Zhang ZY, Li J.
    Front Immunol; 2021 Aug 06; 12():798424. PubMed ID: 35145511
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Multiplexed imaging of tumor immune microenvironmental markers in locally advanced or metastatic non-small-cell lung cancer characterizes the features of response to PD-1 blockade plus chemotherapy.
    Wu F, Jiang T, Chen G, Huang Y, Zhou J, Lin L, Feng J, Wang Z, Shu Y, Shi J, Hu Y, Wang Q, Cheng Y, Chen J, Lin X, Wang Y, Huang J, Cui J, Cao L, Liu Y, Zhang Y, Pan Y, Zhao J, Wang L, Chang J, Chen Q, Ren X, Zhang W, Fan Y, He Z, Fang J, Gu K, Dong X, Zhang T, Shi W, Zou J, Bai X, Ren S, Zhou C, CameL Study Group.
    Cancer Commun (Lond); 2022 Dec 06; 42(12):1331-1346. PubMed ID: 36331328
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Cytotoxic T-lymphocyte-associated protein 4 in gastric cancer: Prognosis and association with PD-L1 expression.
    Pereira MA, de Castria TB, Ramos MFKP, Dias AR, Cardili L, de Moraes RDR, Zilberstein B, Nahas SC, Ribeiro U, de Mello ES.
    J Surg Oncol; 2021 Dec 06; 124(7):1040-1050. PubMed ID: 34255356
    [Abstract] [Full Text] [Related]

  • 14. The association between the tumor immune microenvironments and clinical outcome in low-grade, early-stage endometrial cancer patients.
    López-Janeiro Á, Villalba-Esparza M, Brizzi ME, Jiménez-Sánchez D, Ruz-Caracuel I, Kadioglu E, Masetto I, Goubert V, Garcia-Ros D, Melero I, Peláez-García A, Hardisson D, de Andrea CE.
    J Pathol; 2022 Dec 06; 258(4):426-436. PubMed ID: 36169332
    [Abstract] [Full Text] [Related]

  • 15. HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1.
    Jing CY, Fu YP, Yi Y, Zhang MX, Zheng SS, Huang JL, Gan W, Xu X, Lin JJ, Zhang J, Qiu SJ, Zhang BH.
    J Immunother Cancer; 2019 Mar 18; 7(1):77. PubMed ID: 30885276
    [Abstract] [Full Text] [Related]

  • 16. A comprehensive profiling of the immune microenvironment of breast cancer brain metastases.
    Griguolo G, Tosi A, Dieci MV, Fineberg S, Rossi V, Ventura A, Bottosso M, Bauchet L, Miglietta F, Jacob J, Rigau V, Fassan M, Jacot W, Conte P, Rosato A, Darlix A, Guarneri V.
    Neuro Oncol; 2022 Dec 01; 24(12):2146-2158. PubMed ID: 35609559
    [Abstract] [Full Text] [Related]

  • 17. Clinicopathologic implications of immune classification by PD-L1 expression and CD8-positive tumor-infiltrating lymphocytes in stage II and III gastric cancer patients.
    Koh J, Ock CY, Kim JW, Nam SK, Kwak Y, Yun S, Ahn SH, Park DJ, Kim HH, Kim WH, Lee HS.
    Oncotarget; 2017 Apr 18; 8(16):26356-26367. PubMed ID: 28412752
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Whole-transcriptome sequencing in advanced gastric or gastroesophageal cancer: A deep dive into its clinical potential.
    Hashimoto T, Nakamura Y, Mishima S, Nakayama I, Kotani D, Kawazoe A, Kuboki Y, Bando H, Kojima T, Iida N, Shibuki T, Imai M, Fujisawa T, Nagamine M, Sakamoto N, Kuwata T, Yoshino T, Shitara K.
    Cancer Sci; 2024 May 18; 115(5):1622-1633. PubMed ID: 38429886
    [Abstract] [Full Text] [Related]

  • 20. The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer.
    Imai D, Yoshizumi T, Okano S, Uchiyama H, Ikegami T, Harimoto N, Itoh S, Soejima Y, Aishima S, Oda Y, Maehara Y.
    Cancer Med; 2017 Jul 18; 6(7):1614-1626. PubMed ID: 28602029
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.